
Prior authorization for medication, often called a PA for medication, is a health plan’s approval of a drug before it pays for it. The prescriber’s office submits the request, and the benefit that covers the drug decides who reviews it. A drug the patient fills at a pharmacy usually goes to the plan’s pharmacy benefit manager. A drug your practice gives in the office, such as an infusion or an injection, usually goes to the health plan under the medical benefit.
The route matters because denials are common. 32% of physicians say their prior authorization requests are often or always denied, according to the AMA’s May 2026 survey of 1,000 physicians. A medication request sent to the wrong reviewer, or sent without the treatment history the plan’s policy asks for, comes back before anyone weighs the clinical case.
Every medication request starts by finding the benefit that pays for the drug, because the benefit decides who reviews the request and which rules it is judged against. A prescription prior authorization for a drug filled at a pharmacy is judged against the plan’s formulary. A drug your practice gives is judged against the health plan’s medical drug policy.
Medicare draws the line by where the drug is given. Part B usually covers drugs a patient would not give themselves, such as those given in a doctor’s office or a hospital outpatient setting, and Part D covers many drugs that Part B does not, according to Medicare’s guide to outpatient prescription drugs. Commercial and Medicaid plans also split drugs between a pharmacy and a medical benefit, and each plan’s policies say which drugs sit where.
The table compares the two routes.
| Route | Typical drugs | Who reviews the request | When to submit | How to submit |
|---|---|---|---|---|
| Pharmacy benefit | Drugs filled at a retail, mail-order or specialty pharmacy | The plan’s pharmacy benefit manager | When prescribing, or after the pharmacy claim is rejected | Electronically from the EHR or the manager’s portal, or by fax |
| Medical benefit | Drugs your practice gives, such as infusions and injections billed with HCPCS codes | The health plan, or a company it delegates review to | Before the drug is given | Through the health plan’s or the delegate’s provider portal |
Some payors review behavioral health benefits separately from medical benefits, sometimes through a separate company. When a patient’s plan works that way, confirm which reviewer handles the request before you submit it.
Coverage also changes over time. Many plans reset in January, and a patient’s benefits and authorization requirements can change with them. HealthPRO Heritage, a post-acute therapy provider, completed more than 10,000 benefit checks with Silna in under seven days in January 2026. The same work took nearly 60 days the year before.
“Before Silna, January meant accepting that nearly $1 million in earned revenue was at risk. That’s no longer the conversation we’re having.”
A complete request meets the plan’s criteria for the drug the first time it is reviewed. Before you submit, check that it includes:
Medicare drug plans must decide a standard coverage determination no later than 72 hours after they get the request, and an expedited one no later than 24 hours, according to CMS’s August 2025 prescriber guide to Part D. A request qualifies as expedited when the standard timeframe could seriously jeopardize the patient’s life, health or ability to regain maximum function.
Medicare Advantage plans must meet the same limits for Part B drugs, the drugs covered under the medical benefit: 72 hours for a standard request and 24 hours for an expedited one, under federal regulations 42 CFR 422.568 and 42 CFR 422.572 as of October 2026.
Commercial plans follow state rules and their own policies. CMS’s newest limits, in effect since January 1, 2026, require Medicare Advantage, Medicaid and CHIP plans to decide prior authorizations within 72 hours for urgent requests and seven calendar days for standard ones. Those limits cover medical services and exclude drugs, according to the CMS fact sheet of January 17, 2024.
Physicians in the AMA’s May 2026 survey also linked prior authorization to harm to patients.
The prescriber’s office, usually staff working from the prescriber’s notes. When a claim is rejected for lack of prior authorization, pharmacy staff tell the office, but the clinical case comes from the prescriber.
Send a complete request electronically when the drug is prescribed, so the review starts before the patient’s fill or appointment. When waiting could seriously harm the patient’s health, ask for an expedited review, which a Medicare drug plan must decide within 24 hours.
Each pharmacy benefit manager and health plan publishes its own forms, often one for each drug or drug class. Many accept the same information electronically from the EHR or a portal in place of a faxed form.
Until the end date the plan sets, which is often tied to a course of treatment or the plan year. A patient who joins a new Medicare drug plan may get a one-time, 30-day transition fill of a drug they already take while the new plan’s prior authorization is requested, according to Medicare’s drug plan rules as of October 2026.
The denial notice gives the reason, which decides the next step. A request sent under the wrong benefit is usually fixed by sending it to the right reviewer, without using an appeal.
For pharmacy-benefit drugs, yes. The pharmacy benefit manager reviews them against the formulary, while procedures go to the health plan under its medical policy. A drug your practice gives usually follows the procedure route.
This article is general educational information and does not give medical or insurance advice. Coverage rules and clinical criteria vary by plan and state, so consult a licensed healthcare professional or your plan administrator about your specific situation.
Jeffrey Morelli
Jeffrey Morelli is the Co-Founder and CEO of Silna Health, the first Care Readiness Platform built to remove the administrative barriers that delay care. Silna automates benefit checks, eligibility, and prior authorizations across 1,000+ payors, and is backed by $27M from Accel and Bain Capital Ventures. Before Silna, Jeff spent a decade in San Francisco building and scaling products for highly regulated industries, including leading go-to-market at Truework (Series C, acquired by Checkr).
Last updated: October 13, 2026.